相关临床试验
111
21 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1946
进行中（未招募）
9
8.1%
已完成
61
55.0%
尚未招募
12
10.8%
招募中
24
21.6%
终止
2
1.8%
Unknown
2
1.8%
撤回
1
0.9%
暂无批准数据
- Professor Kim V. Narry of IBS and Seoul National University has been selected as the 2027 HFSP Nakasone Award recipient, the first Korean and first Asian scientist to receive this honor. - The award recognizes her lab's discovery of non-canonical RNA tailing pathways, including mixed tails where guanine intersperses within poly(A) tails, dramatically enhancing mRNA stability. - Her team's technology extends mRNA lifespan up to fourfold by increasing tail length from 60–70 to 180–200 nucleotides, enabling protein production for one to two weeks. - The breakthrough opens the door to mRNA-based therapies for intractable diseases by potentially reducing dosage and injection frequency while lowering side effects.
- Researchers at IBS and Seoul National University have revealed the first near-atomic resolution structure of the Argonaute maturation complex, showing how chaperone proteins hold Argonaute in an open conformation for miRNA loading. - The study demonstrates that miRNA is not passive cargo but an active molecular cofactor that directly guides Argonaute protein folding, a finding that reshapes understanding of RISC assembly. - An experimental system was established that reproduces Argonaute loading outside cells, enabling direct evaluation of how chemical modifications in therapeutic siRNAs affect assembly and function. - The findings, published in Nature, provide a molecular framework for rational RNA therapeutic design, moving beyond the trial-and-error approaches that have dominated the field.
- The Coalition for Epidemic Preparedness Innovations (CEPI) has awarded up to $16 million to a Korean consortium led by the International Vaccine Institute to develop the world's first mRNA vaccine against Severe Fever with Thrombocytopenia Syndrome (SFTS). - The project utilizes artificial intelligence and structure-based design to create vaccine candidates using ST Pharm's proprietary SmartCap® and STLNP® platform technologies, marking the first time an SFTS vaccine will be tested in humans. - SFTS, transmitted by ticks in East Asia, causes high fever, thrombocytopenia, and potential multiple organ failure with no current commercial vaccine available. - The research aims to establish a prototype vaccine for the Phenuivirus family that could accelerate development of vaccines against similar emerging viruses within 100 days during future outbreaks.
- Samsung Bioepis is exploring the acquisition of its U.S. sales partner Organon as part of a strategic shift from indirect to direct sales to capture higher profit margins and strengthen market control. - The company has already begun transitioning to direct sales in Europe, reclaiming commercialization rights for Byooviz from Biogen and now directly selling four products in the European market. - This strategic pivot comes as Samsung Bioepis faces intensifying biosimilar competition and seeks to maximize cash generation to fund its new drug development pipeline, including ADC candidates developed with partners like IntoCell. - The move aligns with broader industry trends as drug price-cut policies create opportunities for biosimilar companies while increasing competitive pressure in the global market.
- Researchers from Seoul National University and Korean institutions developed a wireless implantable drug delivery system that uses Near-Field Communication (NFC) technology to deliver anticancer drugs deep into solid tumors without harming healthy tissue. - The Dual-Phoretic Wireless Drug Delivery System (DPw-DDS) achieved over four times greater drug delivery efficiency than standard injection methods and reduced tumor volume by more than 50% within five weeks in vivo experiments. - The system integrates electrophoresis and iontophoresis mechanisms in a compact subcutaneous implant, eliminating the need for external wiring or batteries while supporting various drug types including nanomedicines and mRNA therapeutics. - The platform does not require drug reformulation and can be applied to existing therapeutics, potentially reducing development costs and time while offering applications beyond cancer treatment.
